Dongsheng Buys Cardiovascular Drug for $1.5 Million

Dongsheng Pharmaceutical International Co. acquired all rights, including IP and manufactruing, for a vasodilator drug from Shanghai Wan'Te Pharmaceutical Co. for 10 million RMB ($1.5 million). Micro-emulsion alprostadil injection is the second most widely used cardiovascular disease treatment in China hospitals, according to the company. Dongsheng plans to begin marketing the drug in March 2011. More details.... Stock Symbol: (OTCBB: DNGH)